StabiLux Biosciences, Inc
Houghton, MI · CIK 0002023675 · Biotech · Private
Fluorescent probes based on high-brightness fluorophores for viral RNA detection in qPCR assays
- Grants
- $2.0M
- 3 awards
- Sector median: 1
- Raised
- $554K
- 1 Form D · May 2024
- 29 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | National Science Foundation · Phase I · STTR Phase I: High Brightness Fluorophores for Bioscience Applications | $241,000 | |
| Federal grant | National Science Foundation · Phase II · STTR Phase II: High Brightness Fluorophores for Bioscience Applications | $1,549,997 | |
| Federal grant | National Science Foundation · Phase I · STTR Phase I: COVID-19 - High-Brightness Fluorescent Probes for Quantitative Polymerase Chain Reaction | $256,000 | |
| Private capital raised | Form D · SEC | $554,381 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1525 | Jabez Biosciences, Inc. | — | $3.9M |
| 1526 | DRAGONASE LLC | — | — |
| 1527 | Element Genomics, Inc. | — | $4.8M |
| 1528 | StabiLux Biosciences, Inc | — | $554K |
| 1529 | PGI HOLDING CORPORATION | — | — |
| 1530 | EUNOIA BIO TECH, LLC | — | — |
| 1531 | Juno Therapeutics, Inc. | — | $1.0B |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- MARK EHLERTDirector
- JONATHAN LEINONENDirector · Executive Officer
- MICHAEL MORTLOCKExecutive Officer
- JOHN RANSOMDirector
- STEVE TOKARZDirector · Executive Officer
- YOKE YAPDirector · Executive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.